Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Ritlecitinib with or without UVB light therapy
Official title: Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo Prospective Multicentric Evaluator Blinded Interventional Study
Status: Recruiting now
Description:
Centre Hospitalier Universitaire de Nice plans to enroll about 56 participants. Ritlecitinib is an oral immune-modulating drug that blocks JAK3 and TEC-family signaling. Researchers hope it will reduce the immune attack on melanocytes and support repigmentation. Ritlecitinib is sold as Litfulo and is approved for severe alopecia areata in people age 12 and older; vitiligo would be a new use. Possible effects include headache, diarrhea, acne, and infections. People age 18 and older may qualify. The study is recruiting at 5 listed sites in France.
Start date: March 12, 2026
Completion date: June 01, 2029
Organizer: Centre Hospitalier Universitaire de Nice
Contact: Thierry Passeron, PhD
Tel.: +33 492 036 488
Email: passeron.t@chu-nice.fr
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- How can I explain vitiligo to my children?
Vitiligo can be confusing for children because it doesn’t resemble an "illness" in the typical sense. Choosing the right way to explain it depends on your child’s age and maturi...
- What is vitiligo?
Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Contr...
- Awareness Days Similar to World Vitiligo Day
World Vitiligo Day, celebrated annually on June 25 since 2012, is a significant event dedicated to raising awareness about vitiligo and supporting those affected by the conditio...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.